Rick,
The average Harvard MBA IS a no-brainer
(on behalf of The U of C, Wharton and Stanford) <g>.
I do have to agree with Jeff on this point: If a non-scientist agrees with the assessment that third-tier biotechs are vastly undervalued, and they want to play that, then they have to have a strategy. Picking companies with a solid pedigree, good management and other sound non-science fundamentals is probably not a bad one. Yes, it's higher risk than transportation stocks, but the expected reward is also much higher.
To me these are some of the strengths of GZMO vs. some of the other bleeding edge oncology third-tiers, and they are strengths even for the scientist.
With technical understanding, the well-read scientist almost has an arbitrage opportunity over the average investor. The expected return is the same, while (hopefully) the risk is lower for the technologically informed. (Though sometimes we miss the business trapdoors; hopefully GZMO never finds any of those)
biowa |
